1483 related articles for article (PubMed ID: 32849491)
21. Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche.
Rajayi H; Tavasolian P; Rezalotfi A; Ebrahimi M
Int Rev Immunol; 2019; 38(6):267-283. PubMed ID: 31578892
[TBL] [Abstract][Full Text] [Related]
22. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes.
Alqarni A; Jasim SA; Altalbawy FMA; Kaur H; Kaur I; Rodriguez-Benites C; Deorari M; Alwaily ER; Al-Ani AM; Redhee AH
J Biochem Mol Toxicol; 2024 Jun; 38(6):e23719. PubMed ID: 38764138
[TBL] [Abstract][Full Text] [Related]
23. Cancer stem cells: a new framework for the design of tumor therapies.
Garvalov BK; Acker T
J Mol Med (Berl); 2011 Feb; 89(2):95-107. PubMed ID: 20890588
[TBL] [Abstract][Full Text] [Related]
24. Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications.
Paul R; Dorsey JF; Fan Y
Pharmacol Ther; 2022 Mar; 231():107985. PubMed ID: 34480963
[TBL] [Abstract][Full Text] [Related]
25. Targeting Stemness: Implications for Precision Medicine in Breast Cancer.
Liang ZM; Chen Y; Luo ML
Adv Exp Med Biol; 2017; 1026():147-169. PubMed ID: 29282683
[TBL] [Abstract][Full Text] [Related]
26. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.
Cheng JY; Hung JT; Lin J; Lo FY; Huang JR; Chiou SP; Wang YH; Lin RJ; Wu JC; Yu J; Yu AL
Front Immunol; 2021; 12():791551. PubMed ID: 35046949
[TBL] [Abstract][Full Text] [Related]
27. Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives.
Fanali C; Lucchetti D; Farina M; Corbi M; Cufino V; Cittadini A; Sgambato A
World J Gastroenterol; 2014 Jan; 20(4):923-42. PubMed ID: 24574766
[TBL] [Abstract][Full Text] [Related]
28. Cancer stem cells: perspectives for therapeutic targeting.
Maccalli C; De Maria R
Cancer Immunol Immunother; 2015 Jan; 64(1):91-7. PubMed ID: 25104304
[TBL] [Abstract][Full Text] [Related]
29. Resistance to Cell Death and Its Modulation in Cancer Stem Cells.
Safa AR
Crit Rev Oncog; 2016; 21(3-4):203-219. PubMed ID: 27915972
[TBL] [Abstract][Full Text] [Related]
30. Cancer stem cells in human gastrointestinal cancer.
Taniguchi H; Moriya C; Igarashi H; Saitoh A; Yamamoto H; Adachi Y; Imai K
Cancer Sci; 2016 Nov; 107(11):1556-1562. PubMed ID: 27575869
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer stem cells as novel biomarkers.
Ray SK; Mukherjee S
Clin Chim Acta; 2024 Apr; 557():117855. PubMed ID: 38453050
[TBL] [Abstract][Full Text] [Related]
32. Cancer stem cells (CSCs) in cancer progression and therapy.
Najafi M; Farhood B; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of cancer stem cell senescence: Current understanding and future perspectives.
Zhang DY; Monteiro MJ; Liu JP; Gu WY
Clin Exp Pharmacol Physiol; 2021 Sep; 48(9):1185-1202. PubMed ID: 34046925
[TBL] [Abstract][Full Text] [Related]
34. Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance.
Makena MR; Ranjan A; Thirumala V; Reddy AP
Biochim Biophys Acta Mol Basis Dis; 2020 Apr; 1866(4):165339. PubMed ID: 30481586
[TBL] [Abstract][Full Text] [Related]
35. Cancer and Cancer Stem Cells: New Molecular Perspectives.
Gurel C; Inetas G; Hortu I; Tunc E; Kuscu GC; Dindaroglu FC; Sahin O; Buhur A; Oktem G
Crit Rev Oncog; 2019; 24(1):99-104. PubMed ID: 31679224
[TBL] [Abstract][Full Text] [Related]
36. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
37. Cancer stem cell (CSC) resistance drivers.
Najafi M; Mortezaee K; Majidpoor J
Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
[TBL] [Abstract][Full Text] [Related]
38. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
39. Cancer Stem Cells and Anti-tumor Immunity.
Yılmaz M; Kaplan F; Mender I; Gryaznov SM; Dikmen ZG
Curr Stem Cell Res Ther; 2023; 18(4):445-459. PubMed ID: 36263477
[TBL] [Abstract][Full Text] [Related]
40. Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.
Nishi M; Akutsu H; Kudoh A; Kimura H; Yamamoto N; Umezawa A; Lee SW; Ryo A
Oncotarget; 2014 Sep; 5(18):8665-80. PubMed ID: 25228591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
